81. The name of the new prostate cancer drug is ____.

1. therapeutic cancer vaccine
2. unknown
3. Dendreon
4. Provenge

82. The FDA could be criticized ____.

1. for its turning-down the license for Provenge
2. because of an endorsement by one of the agency's advisory committees
3. owing to patients' own immune system to fight the cancer
4. because of the two-week spaced treatment of prostate cancer

83. Two prostate cancer experts hired bodyguards attending a major conference ____.

1. because they had been threatened for recommending the FDA to deny the drug trial
2. after the FDA's decision two years ago agitated prostate cancer patients and investors
3. before the FDA had delayed the production of the prostate cancer vaccine
4. when investors from Dendreon denied prostate cancer patients a potential treatment

84. What does the author say about the results of the prostate cancer drug trial?

1. Patients no longer benefited from therapies intended to deprive the tumors of testosterone.
2. Patients' cancer had spread beyond the prostate gland.
3. Many investors bet on the failure of the drug in the clinical trial.
4. The company did not disclose the results for some reason.

85. Which of the following best describes the new prostate cancer drug trial?

1. Controversial.
2. Notorious.
3. Promising.
4. Susceptible.

(Reference keys.)